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ATM is a serine-threonine kinase that is activated in response to DNA double strand 
breaks and is an important sensor for proper repair. Individuals with biallelic mutations in 
ATM have a fivefold increased risk of developing leukemia or lymphoblastic lymphomas. 
Recent investigations reveal that Ataxia-telangiectasia (AT) mutation carriers have an 
increased risk of developing breast cancer, especially in younger women. To understand 
further the interplay between ATM and breast cancer susceptibility genes, we initiated 
studies to investigate the contribution of simultaneous loss of ATM and BRCA function 
in multiple cell culture based models. We utilized various approaches to investigate the 
role of ATM in multiple BRCA backgrounds including RNA interference, clonogenic 
survival and Bacterial Artificial Chromosome engineering to study downstream signaling 
efficiency, sensitivity to therapy, cell cycling and transformability.  
 
ATM missense and deletion near the PI3-kinase domain was created by BAC 
recombineering and used to transfect into ATM null cells (AT-Tert) to study its function. 
Missense mutation expression appears to dramatically affect long term survival of AT-
Tert cells in culture. Deletion of the FATC domain in ATM on the other hand, did not 
affect cell survival or dramatically alter growth in culture suggesting that basal level of 
kinase function is maintained. The missense allele however functions as a dominant 
negative and seems to have a dysregulatory effect on telomerase function. 
 
 xii
ATM knockdowns in various BRCA backgrounds were achieved by RNA interference. 
ATM-mediated Chk2 signaling in all the cell lines tested correlated directly with the 
levels of ATM knockdown achieved. However when assessed for short term survival 
after genotoxic drugs (BCNU, MMS and MMC) treatment or gamma irradiation, various 
BRCA backgrounds exhibited differential sensitivity and survival responses. 
 
Assessment of the expression profile of the knockdown and control cells using a PCR 
array of 84 genes involved in the cell cycle pathway revealed that Bcl2, p21, Cul2 and 
Rad9 were differentially regulated. Their altered expression may provide explanations for 
the differential responses observed on ATM knockdown in cells further compromised for 
BRCA functions.  
 
Taken together, our data suggests that ATM may regulate other signaling pathways via its 
ability to interact with BRCA1 and/or BRCA2 and that loss of multiple functions, often 




1.1.  Ataxia Telangiectasia Mutated 
 
Ataxia-telangiectasia (AT) is an autosomal recessive condition with an estimated 
frequency of 1 in 40,000 to 1 in 300,000 in Caucasian populations (Swift et al., 1986). It 
is characterized by progressive cerebellar ataxia, oculomotor apraxia, choreoathetosis, 
telangiectasias of the conjunctivae, immunodeficiency, frequent infections, an increased 
risk of malignancy and sensitivity to ionizing radiation (Chun and Gatti, 2004; Taylor and 
Byrd, 2005). AT individuals are estimated to have a 100-fold increased risk of cancer 
compared with the general population. Lymphoid cancers predominate in childhood, and 
epithelial cancers, including breast cancer, are seen in adults (Morrell et al., 1986). Over 
10% of AT patients develop cancer at an early age. Thorstenson et al. (2003) mapped 137 
sequence alterations in the ATM gene from 270 Austrian hereditary breast cancer or 
ovarian cancer families. 
 
Individuals heterozygous for ATM, about 1% of the general population, may have an 
increased predisposition to cancer, in particular breast cancer. AT carriers have been 
shown to be 5.5 times more likely to develop breast cancer than non-carriers. It is likely 




The gene for ataxia-telangiectasia (ATM) was mapped to chromosome 11q by genetic 
linkage analysis in 1988 and was identified by positional cloning in 1995 (Gatti et al., 
1988; Savitsky et al., 1995). The ATM gene is located at chromosome 11q22.3 and 
consists of 66 exons, 64 of which encode a protein of 3056 amino acids (Savitsky et al., 
1995).  
 
ATM belongs to a protein family known as the PI3K-related protein kinases (PIKK) 
(Abraham, 2004). These proteins are characterized by a domain similar to that in 
phosphatidylinositol 3-kinase. Most PIKKs including ATM, are active serine/threonine 
kinases. ATM also contains a FAT domain (FRAP, ATM, TRAPP), and a highly 
conserved C-terminal FATC domain (Bosotti et al., 2000). The FATC domain appears to 
be important for regulating the kinase activity of ATM and for binding regulatory 
proteins (Jiang et al., 2006). The N-terminal regions of ATM include several HEAT 
domains that may influence interactions with other proteins (Perry and Kleckner, 2003) 
and a region essential for substrate binding (Fernandes et al., 2005). Other putative 
motifs, including an incomplete leucine zipper and a proline-rich region that binds c-Abl, 




Fig 1: Representation of ATM protein depicting various regions of possible function or 
interaction. The kinase activity attributable to the PI3-kinase domain of ATM is currently 
its only established function. (adapted from Lavin et al., 2004) 
 
1.2. ATM mediated signalling 
 
ATM plays a central role in the repair of DNA double-strand breaks. The response to 
DNA damage includes numerous processes such as recognition of damaged DNA, 
recruitment of repair proteins, signalling to cell cycle checkpoints, transcriptional 
regulation and activation of apoptosis. In normal cells ATM exists as inert dimers or 
multimers. In response to double-strand DNA breaks, ATM dissociates to highly active 
monomers (Bakkenist and Kastan, 2003). During this process, ATM undergoes 
autophosphorylation on Ser1981 and is recruited to the sites of DNA damage. This 
initiates a signalling cascade through phosphorylation of multiple DNA damage response 
and cell-cycle proteins, including proteins encoded by cancer susceptibility genes such as 
TP53, BRCA1 and CHEK2. 
 4
 
The autophosphorylation of ATM at Ser1981 is a crucial event for activation of signaling 
(Bakkenist and Kastan, 2003). It was demonstrated that as few as two strand 
breaks/genome, introduced by the restriction enzyme I-SceI, could induce ATM 
autophosphorylation on Ser1981. They also noted that greater than 50% of ATM is 
autophosphorylated by 15 min after exposure to 0.5Gy of radiation, a dose that would 
induce 15-20 DNA dsb/cell (Lavin and Kozlov, 2007). It is likely that mutations mapping 
to the kinase domain possibly cause inactivation of the PI3-kinase activity and gives rise 
to AT. Sequence alterations in ATM immediately adjacent to the kinase domain are also 
likely to influence the function of the protein’s kinase activity. 
 
 
1.3. ATM and DNA damage responses 
 
ATM activation in response to IR is dependent on the function of Mre11, Rad50, and 
Nbs1, which form a functional complex with helicase and nuclease activities (MRN 
complex). The MRN complex acts as a sensor for DNA breaks and is required for DSB-
induced ATM signaling. MRN complex binds to ATM, inducing conformational changes 
that facilitate an increase in the affinity of ATM toward its substrates. The MRN complex 
first detects the DSB by binding to the broken ends. Once bound, the MRN complex then 
recruits and promotes the activation of ATM (Lee and Paull, 2005; Paull and Lee, 2005). 
Falck et al. (2005) identified an ATM interaction motif within the C terminus of Nbs1, 
which is required for the retention of ATM to sites of DNA damage, and the activation of 
checkpoint pathways. Regardless of which protein physically recognizes the DSB, there 
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appears to be mutual promotion of activity between the MRN complex and ATM. ATM 
phosphorylates Nbs1, and the MRN complex enhances ATM kinase activity. 
Furthermore, Nbs1 contains a BRCT (BRCA1 C terminal) domain, and a FHA (fork-head 
associated) domain. Both domain types have been shown to bind phosphorylated 
proteins, suggesting that Nbs1 may bind other ATM targets after phosphorylation to 
modulate their activity. 
 
 IR produces DNA strand breaks. Ismail et al. (2005) found that the number of DNA 
double strand breaks (DSBs) correlates closely with the ATM activity in the cells, 
whereas no correlation was found with the number of single strand breaks (SSBs). 
Further, they reported that ATM is directly activated by the few DSBs that are introduced 
by IR. In parallel experiments, no Chk2 phosphorylation was observed in AT cells, 
indicating that all Chk2 phosphorylation was attributable to ATM kinase activity. Hence, 
ATM is central to the cellular response to IR and phosphorylates several key proteins, 
such as Chk2 and p53, resulting in cell cycle arrest. (Ismail et al., 2005) 
 
ATM phosphorylates and controls several signaling pathways that are activated by 
gamma irradiation (IR). An example is the regulation of cell cycle checkpoints. Important 
substrates include the p53 protein, which mediates the G1/S checkpoint and Chk2 which 
activates the G2/M checkpoint. ATM directly phosphorylates p53 on S15 and a number 
of other sites which modulates the transcriptional activity of p53. In addition, Mdm2, a 
negative regulator of p53 is also phosphorylated at S395 by ATM. Mdm2 is an E3 
ubiquitin ligase that promotes p53 ubiquitination and nuclear export for proteosomal 
degradation in the cytoplasm. ATM-mediated phosphorylation of Mdm2 on Ser395 
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decreases the ability of Mdm2 to shuttle p53 from nucleus to cytoplasm for its 
degradation, resulting in nuclear accumulation and stabilization of p53 in response to IR. 
p53 induces the transcription of Cdk inhibitor p21 which inhibit Cyclin dependent kinase 
2 (Cdk2), thus preventing the progression from G1 to S-phase. (Lavin and Kozlov, 2007) 
 
Under normal conditions, the phosphatase Cdc25C removes the phosphate group from 
Cdc2 at tyrosine 15 to allow Cdc2-cyclin B kinase to facilitate mitotic entry. Irradiation 
causes ATM to phosphorylate Chk2 which in turn phosphorylates Cdc25C. This causes 
Cdc25C to bind to 14-3-3 protein which sequesters it to the cytoplasm and away from its 
substrate. This results in a G2/M checkpoint control.   
 
Cells from AT carriers are intermediate in radiosensitivity. Mutations of the ATM kinase, 
as in cells deriving from ataxia telangiectasia (AT) patients, result in hypersensitivity to 
drugs such as etoposide and are accompanied by an increased rate of chromosomal 
aberrations.  AT cells exhibit decreased levels of survival to etoposide in all phases of the 
cell cycle and show nearly 2-fold higher levels of chromosome damage in G1 and G2 
phase compared to normal cells. The activation of ATM in response to etoposide 
eventually leads to the formation of MRN complex foci similar to those induced by IR. 
(Montecucco and Biamonti, 2007) 
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1.4. ATM and telomere stability 
 
 
Cells derived from AT patients and ATM-deficient mice show slow growth in culture and 
premature senescence. Cells from AT individuals displayed abnormalities in culture such 
as cytoskeletal defects and hypersensitivity to ionizing radiation. They also showed end-
to-end associations involving telomeres. Telomeres, consisting of (TTAGGG)n repeats 
and associated proteins, protect chromosomes from end fusions, incomplete replication 
and exonuclease degradation. Hande et al. (2001) reported that the functional inactivation 
of ATM leads to telomere shortening, chromosome instability and the occurrence of 
extrachromosomal fragments of telomeric DNA. This suggests an important role for the 
mammalian ATM gene in maintaining telomere integrity. 
 
Human telomeres are coated with a telomere-specific complex, which includes TRF1. 
TRF1, a sequence-specific duplex DNA–binding protein functions not only to protect 
telomeres from being recognized as double-strand breaks but also to promote telomere 
shortening. Recent studied by Wu et al. (2007) demonstrated that MRN and ATM 
function together to control TRF1 binding to telomeres. As ATM phosphorylates TRF1, 
the phosphoryated TRF1 dissociates from telomere, leading to increased access of 
telomerase to the ends of telomeres. 
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1.5. Clinical significance of ATM loss 
 
Swift et al. (1987) first proposed that relatives of ataxia-telangiectasia patients might be 
at increased risk of breast cancer. His analysis of cancer incidence in 110 ataxia-
telangiectasia families suggested that the relative risk of cancer was 2.3 for men and 3.1 
for women, with breast cancer being the most strongly associated cancer. This 
observation was clearly of importance to ataxia-telangiectasia families, but also had 
potential wider significance given that it was estimated that up to 1% of the population 
might be carriers of an ataxia-telangiectasia predisposing mutation. 
 
Thus, even a relatively modest increase in breast cancer risk in carriers could equate to an 
appreciable population attributable risk. Several other epidemiological surveys of cancer 
incidence in relatives of ataxia telangiectasia cases have since been conducted (Easton, 
1994, Thompson et al., 2005). These multiple epidemiological studies have provided 
evidence for an increased risk of cancer, notably breast cancer, in the relatives of AT 
patients.  A link between ATM missense mutations and breast cancer was subsequently 
established by Lavin et al. in 2005.  
 
Of all breast cancers, 6.6% may occur in women who are AT mutation carriers. The 
increased risk for breast cancer for AT family members has been most evident in younger 
women, leading to an age-specific risk model predicting that 8% of breast cancer cases in 
women under the age of 40 arise in AT carriers, compared to 2% cases between 40-59 
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years old (Hall, 2005). Similarly loss of BRCA1/2 function has been established to be the 
major contribution towards early onset familial breast and ovarian cancers. Over 25% of 
these alterations in BRCA1 and 40% in the case of BRCA2 are single base changes 
classified as variants of unknown function. It will therefore be important to not only 
understand the contributions of missense mutations in ATM to cancer susceptibility but 
there is a clear need to investigate the interplay of multiple functional losses led cancers 




The objective of this study is to obtain information on how ATM can contribute to cancer 
susceptibility. This is particularly of interest as AT carriers are known to be predisposed 
to breast cancer.  
 
Given that the hereditary breast cancer susceptibility genes, BRCA1 and BRCA2 
contribute to a significant number of breast cancer cases and that they function to 
maintain genomic stability, we decided to investigate the requirements of BRCA gene 




1.7.  Approaches 
 
1.7.1.  Bacterial Artificial Chromosomes (BAC) recombineering 
 
BACs (and PACs) are vectors that carry large inserts stably and in this case, a 
95kb Atm carrying genomic region. These vectors are maintained in recombinase 
null bacterial cells where they are kept at low copy numbers of 1/2 per cell. BAC 
recombineering allows generation of subtle alterations such as single base 
changes, deletions and insertion in large genes without causing disruptions to 
coding (Swaminathan et al., 2001; Swaminathan and Sharan, 2004; Court et al., 
2003).  
 
The procedure utilises homologous recombination in recA- E. coli transiently 
allowing ‘exo’, ‘bet’ and ‘gam’ functions, expressed under the stringent control of 
a temperature-sensitive repressor. DH10B bacterial cells (recA-) are maintained at 
32oC under standard conditions and are induced at 42oC for 15 min for expression 
of ‘bet’ and ‘gam’ proteins. The use of a 100mer targeting vector which harbors 
mutation such as single base changes, deletions or insertion, and with homology 
arms of 35 or more bases allow effective homologous recombination after cells 
are induced. ‘Bet’ allows homology mediated direction of the targeting vector and 
‘gam’ functions as a RecBCD nuclease and stabilizes the exogenous DNA 
(oligonucleotides in this case). Inclusion of ‘exo’, a 5’→3’ exonuclease allows for 
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the use of PCR products as targeting vectors. Since the targeting vector does not 
include a selectable marker, both high frequency of recombinant generation and 
efficient screening for identification are crucial to the success of the procedure.  
 
After the BAC containing cells are electroporated with the targeting vector, 
screening for recombinants is performed using a rapid and specific 2-step 
mismatch PCR. The mismatch primer for detection bears a penultimate base 
mismatch with respect to the altered allele and a 2 base 3’ end mismatch with the 
wild type allele. Under the 2 step PCR conditions and when used with a regular 
primers in the reverse direction, the mismatch primer does not support 
amplification from the wild type allele. We used this approach to tailor the BAC 
with a neo resistance construct to allow for mammalian selection; to generate a 
single base change in exon 64 of Atm; and to generate an ATM allele with the C-
terminal FATC domain deleted. 
 
1.7.2. RNA interference 
 
RNA interference (RNAi) is a RNA-guided mechanism for regulation of gene 
expression in which dsRNA induces degradation of the homologous mRNA, 
mimicking the effect of the reduction or loss of gene activity (He and Hannon, 
2004). dsRNA are processed into short interfering RNAs (siRNAs), about 22 
nucleotides in length, by the RNAse enzyme, Dicer. These siRNA are then 
incorporated into a silencing complex called RISC (RNA-Induced Silencing 
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Complex), which identifies and silences complimentary messenger RNAs by a 
process of cleavage and degradation. 
 
Short hairpin RNA (shRNAs) are modeled after miRNA hairpin precursors and 
cloned into pSHAG-MAGIC 2 expression vector. This vector directs the 
transcription of the shRNA by RNA polymerase III and the transcribed shRNAs 
are processed (by Drosha and Dicer) to give siRNA that turns off target gene 
either by translational repression or mRNA degradation. The vector also contains 
elements which allow transfection stability in mammalian cells. ATM 
knockdowns were generated and validated using such an approach. 
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All salts, inhibitors and drugs were obtained from Sigma Aldrich, USA. All tissue culture 
media, reagents and solutions were obtained from Invitrogen Life Technologies, USA. 
All restriction enzymes were obtained from New England Biolabs, UK. 
 
2.2. Cell Lines 
 
HeLa, HCC1937 and Capan-1 (American Type Culture Collection ATCC, USA) were 
used in this study. HeLa is a cervical carcinoma and expresses both functional BRCA1 
and BRCA2 gene products. HCC1937 is a mammary carcinoma and expresses a 
functional BRCA1 but not BRCA2 gene product. Capan-1 is a pancreatic carcinoma that 
expresses a functional BRCA2 but not BRCA1 gene product. HeLa and their ATM 
knockdown cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heat inactivated foetal bovine serum. HCC1937 and their ATM 
knockdown cells were cultured in Rosewell Park Memorial Park 1640 (RPMI 1640) 
supplemented with 10% heat inactivated foetal bovine serum. Capan-1 cells were 
cultured in Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 20% heat 
inactivated foetal bovine serum. AT-Tert cells (a kind gift from Dr Prakash Hande at the 
Department of Physiology, YLL SoM, NUS) were cultured in a 4:1 mix of Dulbecco’s 
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modified Eagle’s medium (DMEM) and Medium 199 supplemented with 10% heat 





BACAtm (identified after screening a RPCI BAC library, CHORI, USA) consists of a 
BAC vector (pBACe3.6) that carries the chloramphenicol resistance gene and a neo 
resistance cassette for mammalian selection and a 96kb insert that includes the full-length 
Atm gene and its regulatory elements. BACAtm was maintained in DH10B cells in 
medium containing 20 μg/ml chloramphenicol at 32oC.  
 
pSHAG-MAGIC 2 (pSM2) containing shRNA targeting ATM was obtained from Open 
Biosystems, USA and maintained as per instructions. The shRNA is designated as A9 
(cat no: RHS1764-9207706) and A12 (cat no: RHS1764-9216279) respectively. 
 
2.4. BAC engineering 
 
2.4.1. Targeting vector design 
 
Single-strand oligonucleotides were used to create a single base change and 
deletion. A 100-mer synthetic oligonucleotide 5'   TGT CTT GAT GAG ACT 
GCA AGA GAA ACT GAA AGG CGT GGA GGA AGG CAC TGA TGG ATC 
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CCA AAA ATC TCA GCC GAC TCT TCC CAG GAT GGA AAG CTT GGG T  
3', was used as a targeting vector to remove nucleotide 94694 to 94737 in 
genomic exon 64 Atm gene. A 80-mer synthetic oligonucleotide, 5’ TTA GTG 
ATA CTG ACC AGA GTT TCA ACA AAG TAG CTG AGC ATG TCT TGA 
TGA GAC TGC AAG AGA AAC TGA AAG GCG TGG AG  3', with a single-
base alteration from G to A in the middle (in bold) was used to alter nucleotide 
position 94643 in exon 64 of Atm gene. 
The oligonucleotides were resuspended in 1x TE and directly used in 
electroporations.  
 
2.4.2. Preparation of competent cells and electroporation 
 
One part of a 3ml overnight culture of BACAtm DH10B cells was scaled up to 50 
parts in LB Cm+ and grown at 32oC with shaking. The cells were grown to an 
OD600 of 0.55-0.6. When indicated, 10ml of the culture was induced at 42oC for 
15min. The induction was stopped rapidly by cooling on ice. The induced and 
uninduced cells were spun at 6000x g in a prechilled rotor for 10 min at 4oC. The 
cells were washed multiple times with ice-cold water to remove all traces of salt 
and finally resuspended in water to a total volume of 50 μl. These 
electrocompetent (uninduced / induced) cells were electroporated with 300ng of 
targeting vector and rescued immediately by the addition of 1ml of SOC. Cultures 
were allowed to recover at 32oC for 1.5 h with shaking. The cells were plated in 
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LB plates containing appropriate antibiotics and incubated for 20-22 h at 32oC or 
diluted and plated in 96 well deep-well format for growth and screening. 
 
2.4.3. Screening for recombinants 
 
Screening was accomplished in a two-step mismatch PCR reaction. The primers 
used for detection of the deletion change in the BAC by mismatch PCR were 
mismatch detection forward primer: 5' GCG TGG AGG AAG GCA CTG ATG 
GA 3'; reverse primer: 5' CAG CAG TAA AGC TCA CTC TGC 3'.  
 
Detection for G to A missense used forward primer: 5' ACA GTT ACC TGT 
TCA CTG TTG 3'; mismatch detection reverse primer: 5' CTT GCA GTC TCA 
TCA AGA CTT 3'. The two-step PCR condition included denaturation for 4 min 
at 94oC followed by 40 cycles of 94oC for 15 s and 60oC for 1 min, and a final 
extension at 72oC for 7 min. The primers amplify a 350 bp product from the 
deletional clone and a 402 bp product from the missense clone but not controls. 
Such identified altered BAC clones were sequence confirmed by Big Dye 
sequencing reaction (Applied Biosystems, USA) and analysed on a ABI PRISM® 




pSM2 carrying shRNA against ATM were transfected into HeLa, HCC1937 and Capan-1 
cells using Lipofectamine reagent (Invitrogen Corporation, USA) by forward 
transfections. AT-Tert cells were transfected using Arrest-in solution (Open Biosystems, 
USA) in a similar procedure. Stable clones were selected for puromycin (Open 
Biosystems, USA) or geneticin (Invitrogen Corporation, USA) and assessed for 
knockdown efficiency by quantitative PCR and western blotting. 
 
2.6.  RNA extraction and first stand cDNA synthesis 
 
RNA extraction was performed using TRIZOL® reagent (Invitrogen Life Technologies, 
USA) as per manufacturer instructions. The dry RNA pellet was resuspended in DEPC-
treated water and estimated by NanoDrop (NanoDrop Technologies, USA).  
 
5 μg RNA was resuspended in 1X DNase I Reaction Buffer to a final volume of 10 µl 
and digested at 37oC for 20 min with 2 units of DNase I. Reaction was stopped by the 
addition of 1 µl of 0.05 M EDTA and the enzyme was inactivated at 75°C for 10 minutes. 
 
First strand cDNA synthesis was performed using SuperScript™ III First-Strand 
Synthesis System (Invitrogen Life Technology, USA) using random hexamers. The 
resulting cDNA was stored at -80oC until further use in quantitative PCR experiments. 
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2.7.  Quantitative PCR (qPCR) 
 
The TaqMan® primer and probe sets for ATM (cat no: HS 00175892_m1) and GAPDH 
(cat no: HS 99999905_m1) from Applied Biosystem were used in qPCR. TaqMan® 
probe was labeled with 6-carboxyfluorescein (FAM) dye at the 5′ end and contained a 
minor groove binder (MGB) and a nonfluorescent quencher (NFQ) at the 3′ end (Applied 
Biosystems, USA). The qPCR reaction was carried out on a ABI 7000 thermocycler 
(Applied Biosystems, USA) in a 20 μl total volume. The cycling conditions used for the 
qPCR were 95oC for 10 min, followed by 40 cycles of 95oC for 15 seconds and 60oC for 
60 seconds. The relative level of mRNA expression of ATM in each sample was 
normalized to the expression of GAPDH mRNA in that sample by the Ct method. 
Each reaction was run in triplicate. 
 
2.8. SuperArray analysis 
 
 
For PCR array experiments, a RT2 Profiler PCR Array (Human cell cycle, APHS-020C) 
was used to simultaneously examine the mRNA levels of 89 genes, including five 
housekeeping genes in a 96-well plate format according to the manufacturer’s protocol 
(SuperArray Bioscience, USA). HeLa, HCC1937, Capan-1 and their respective ATM 
knockdown cells were plated and total RNA was isolated. First strand cDNA synthesis 
was performed using ReactionReady™ First strand cDNA synthesis kit (SuperArray 
Bioscience, USA) and 20 ng cDNA was used for each reaction. The assay was performed 
on 96-well format thermocycler, the ABI 7900HT (Applied Biosystems, USA). The 
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relative level of mRNA expression for each gene in each sample was normalized to the 
expression of housekeeping genes mRNA in that sample by the Ct method. 
 
2.9.  Western blot 
 
Cell lysates were prepared in RIPA lysis buffer (20 mM Tris, 1 mM EDTA, 300 mM 
NaCl and 0.5% NP-40) containing protease inhibitors (0.1 mM PMSF, 5 μg/ml aprotinin, 
5 μg/ml leupeptin, 2 μg/ml pepstatin, 0.1 mM sodium orthovanadate and 1 mM NaF). 
The amount of protein in each lysate was quantitated using the BCA protein assay kit 
(Pierce, USA). A total of 100 μg cellular proteins were analysed by 6% or 12% reducing 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were 
transferred onto Immbilon PVDF transfer membranes (Millipore, USA) by semi-dry 
transfer and probed with the appropriate primary and secondary antibodies. The primary 
antibodies used were mouse monoclonal Pan Actin Ab-5 (NeoMarkers, USA, cat no: 
MS-1295-P0) to detect β actin; rabbit polyclonal anti-ATM Ab-3 (Calbiochem, USA, cat 
no: PC116) to detect full length ATM; rabbit polyclonal Chk2 (Cell Signalling 
Technology, USA, cat no: 2662) and rabbit polyclonal pChk2 (Cell Signalling 
Technology, USA cat no: 2661) to detect Chk2 and phosphorylated Chk2 at Thr68; 
mouse polyclonal BRCA2 Ab-2 (Calbiochem, USA, cat no: PC146) to detect full length 
BRCA2. The secondary antibodies used were Goat Anti-Mouse IgG (H+L)-HRP 
conjugate (Zymed, USA, cat no: 81-6520) and Goat Anti-Rabbit IgG (H+L)-HRP 
conjugate (Santa Cruz, USA, cat no: SC-2030). Signals were detected using the enhanced 
chemiluminescence (ECL) plus system (Amersham Biosciences, USA). 
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2.10.  Immunoprecipitation 
 
Cell lysates (1mg) were precleared with beads and then mixed gently on an orbital shaker 
with an immunoprecipitating antibody; ATM (GeneTex, mouse monoclonal 2C1, USA, 
cat no: GTX70103), BRCA2 (Upstate, mouse monoclonal clone 5.23, USA, cat no: 05-
666) and normal mouse IgG control (Santa Cruz, USA, cat no: SC-2025) at 4oC, 
overnight. The bead bound immune complexes were washed to remove non-specific 
binding. Proteins were eluted from beads by boiling under denaturing conditions and 
analysed by SDS-PAGE. 
 
2.11. Genotoxin sensitivity assays 
 
HeLa, HCC1937, Capan-1 and their respective ATM knockdown cells were treated with 
increasing concentration of BCNU (0-512μM), MMS (0-320μM) or MMC (0-320μM). 
Briefly, the cells were plated at 5000 cells/well one day prior to experimentation. Then 
indicated drug treatments were carried out in serum-free medium for 2 h and cells were 
recovered in medium containing serum for 72 h. The metabolic activity in cells was then 
assayed using the thiazolyl blue MTT assay kit (Sigma-Aldrich, USA) as per 
manufacturer instructions. The results obtained are expressed as the mean values and 
standard deviation of triplicate samples. 
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Cells were also treated with 0 to 10 Gy of gamma irradiation (Physics department, NUS). 
Short term effects were scored by MTT as detailed earlier. 
 
To evaluate the long term effects of irradiation, 300 to 3000 cells were plated in six-well 
plates overnight. Eight hours later, cells were irradiated at a dose of 2 Gy and 10 Gy with 
60Co-γ ray radiation (Gamma Chamber 4000A, India). The medium was replaced after IR 
and cells were incubated for 2 weeks. The colonies obtained were fixed in methanol and 
stained with 1% crystal violet for scoring. Images of colonies were taken using a standard 
scanner. 
 
2.12. Soft agar assay 
 
 
Agar was layered in 2 layers in respective culture medium in this traditional assay for cell 
transformation. The bottom layer was made of 0.5% agar. The top layer consists of cells 
layered on 0.3% agar. Cell viability was assessed using trypan blue dye and a 
hemacytometer before layering. 5000 HeLa cells and 15000 HCC1937 and Capan-1 cells 
were plated. The 6 cm plates were then incubated for 3 weeks at 37oC, 5% CO2 and 95% 
relative humidity. Experiment was carried out in triplicate for each cell line. The colonies 




Cells were cultured on cover slips and fixed in cold methanol for 12 minutes at -20°C. 
Permeability of the cells was increased with 0.1% Triton-X in 1xPBS (Phosphate buffer 
 22
solution, pH 7.4) for 10 minutes at room temperature. After blocking non-specific 
binding with 5% heat inactivated goat serum, samples were incubated in primary 
antibody: mouse polyclonal anti-BRCA1 D9 (Santa Cruz, cat no: SC-6954) to detect C-
terminal BRCA1 and anti-BRCA2 Ab-1 (Neomarkers, cat no: RB-022-P0) to detect N-
terminal of BRCA2, for two hours at room temperature and visualized with secondary 
antibodies which were Alexa 488-labeled Goat Anti-Mouse IgG (H+L) (Molecular 
Probes, cat no: A-11001) and Alexa 568-labeled Goat Anti-Rabbit IgG (H+L) (Molecular 
Probes, cat no: A-11011). Samples were washed once again in 1x PBS to remove 
unbound secondary antibodies and treated with DAPI (4',6-diamidino-2-phenylindole) to 
label the nucleus for 8 minutes at room temperature. A control staining with secondary 
antibody was carried out to assess non-specific interaction of secondary antibody. After 
washing, coverslips were mounted onto slides and images were acquired with a Zeiss 





3.1. Generation of altered alleles of ATM  
 
An ATM carrying BAC was engineered to study the effects of (a) missense alteration in 
exon 64 and (b) loss of a conserve region close to the missense chosen, on ATM 
expression and function. The BAC carrying Atm gDNA and upstream and downstream 
regulatory elements and a neo cassette for mammalian selection (designated BACAtm) 
was altered by recombineering using oligonucleotides without selection markers 
(Swaminathan and Sharan, 2004). In brief, oligonucleotides (80-mers for missense and 
100-mers for deletion generation) targeting sites for alteration were electroporated into 
recombinogenic BAC carrying bacterial cells (Swaminathan and Sharan, 2004). Rescued 
cells were diluted and the transformation efficiency was checked by mismatch PCR. 
Diluted pools were screened by mismatch PCR to identify the presence of altered BACs. 
Both the positive and negative controls were diluted five fold in low salt LB Cm+ 
medium before PCR was undertaken. The negative control consisted of untransfected 
induced cells while the electroporated pool of cells acted as the positive control. Results 
of the mismatch PCR screened for missense generation are presented in Fig 2. No 
amplification was observed in the neat sample as there are too many cells which add 
complexity to the PCR and interfere with the amplification reaction. Specific 
amplification was detected in 10-1 and 10-2 dilutions indicating that the transformation 
efficiency is between 1:2,000 and 1:20,000. The fuzz at the bottom were contributed by 
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excess primers used in the PCR reaction and RNA from bacterial cells. Transformation 
efficiency was estimated based on the total number of colonies generated on LB Cm+ 
plates. The negative control sample did not show any amplification under the PCR 
condition indicating the selectivity of the screen. Based on earlier estimates, the 
electroporated pool was also plated at 50 cells per well in a 96 well deep-well plate for 
subsequent selection of recombinants. Mismatch PCR on the row and column pools of a 
96 well plate was used to rapidly screen 4,800 cells and showed 5 brightly positive wells 
(Fig 3). This decreased the 1:20,000 screening complexity to about 1:1,000. Fig 3 showed 
that Row D/E, Column 2/5/7 were strongly positive. Individual pools from D2, E2, D5, 
E5, D7 and E7 were reconfirmed for alteration by PCR and then individual colonies from 
positive wells were assessed similarly. Lastly, to prove that missense was created 
successfully, sequencing was undertaken. The sequencing result confirmed that a C to T 
conversion was created successfully in exon 64, with a predicted arginine to histidine 




Fig 2: Assessment of transformation efficiency after electroporation in the missense 
clones by a 2-step PCR. Rescued pools of cells were diluted and 10 μl of each sample 




Fig 3: Results of mismatch PCR on row and column pools. The arrows represent the row 
and column pools with recombinant BACAtm (missense). Indicated rows and columns 
were re-screened for recombinants and individual colonies identified from these wells by 




Fig 4: Sequencing result of BACAtm to confirm the missense generation using a reverse 
primer. Arrows indicate the G to A alteration in BACAtm. 
 
Using a similar methodology but a different targeting vector, BACAtm carrying cells 
were electroporated with 100-mer targeting vector and a specific band was detected at  
10-3 dilution by mismatch PCR on pools (Fig 5). As earlier, the induced unelectroporated 
(negative control) pools of cells did not allow amplification from wild type region under 
mismatch conditions. The transformation efficiency observed was between 1:200 to 
1:2,000 in this case, which is higher than the missense clone. It is likely that this region is 
an easier region for manipulation though improvements to the technical expertise of the 
generator can not be ruled out. Assessment of row and column pools was undertaken to 
confirm high recombination frequency (Fig 6). As predicted, all the pools tested were 
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positive. The absence of signal on the negative control indicated specificity of the PCR 
for recombinant clones only. Sequencing of the individual deletion clones identified from 
these pools confirmed the deletion of the FATC domain in BACAtm (Fig 7). The 
manipulated BACs were then transfected into AT-Tert cells to assess their transformation 
potential. 
 
Fig 5: Assessment of transformation efficiency after electroporation using a 100-mer 
targeting vector to create a deletion in BACAtm. Pools of bacterial cells (10 μl) were 




Fig 6: Result of 2 step PCR on row and column pools for identification of BACAtm 
(FATC domain deletion). All the pools (except the negative control) showed 
amplification indicating specificity and a high recombination frequency of at least one 






Fig 7: Sequencing result of BACAtm to verify the deletion of the FATC domain using a 
reverse primer. Shaded region in control indicates the FATC domain that is deleted in the 
altered allele. 
 
3.2. Missense transfected AT-Tert cells exhibit altered growth characteristics 
After obtaining the BACAtm clones, BACAtm DNA was purified by maxiprep 
procedures. AT-Tert cells were transfected with BACAtm DNA using Arrest-In solution 
and selected with Geneticin for 3 weeks. Transfected cells were scored for susceptibility, 
growth and morphological changes. Selection of Geneticin dose was based on nontoxic 
schedule tested on control AT-Tert cells. At this dose AT-Tert cells succumbed in 5 days. 
Fewer number of clones survived selection after BACAtm (missense) transfection than 
after BACAtm (FATC deletion) transfection. AT-Tert cells bearing BACAtm (missense) 
exhibited altered morphology from control cells (Fig 8). It was observed that after stable 
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transfection, AT-Tert cells (BACAtm missense) were arrested in growth and slowly die 
off when cultured over a period of 2 weeks in medium without selection. Hence, no 
further experiments could be done on these cells. On the other hand, AT-Tert cells 
(BACAtm deletion) had similar morphology as control cells. However they exhibited 




Fig 8: Multiple representative images (20x) of untransfected AT-Tert cells (column a), 
transfected AT-Tert with BACAtm (missense, column b) and transfected AT-Tert with 
BACAtm (FATC deletion, column c). AT-Tert BACAtm (missense) cells failed to grow 





















Fig 9: Growth of AT-Tert and AT-Tert (BACAtm deletion) cells assessed in a standard 
3T3 assay. Growth characteristics of the BACAtm (deletion) carrying AT-Tert cells was 
slightly slower in comparison to the control AT-Tert cells. 
 
Our investigations indicated that the disease associated unclassified missense variant of 
Atm tested could possibly function as a null allele. Unfortunately, much could not be 
assessed due to the failure of cells to maintain in culture. The deletion bearing BAC 
transfected cells possibly allowed for ATM function as the loss of the C-terminal FATC 
domain did not dramatic alter the Atm protein expression or function. A recent study on 
this region by Jiang et al. in 2006 also found that the FATC domain is important for 
regulating the kinase activity of ATM. Hence further characterization of the deletion 
clone was not pursued.   
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3.3. Screening and verification of ATM knockdowns 
We decided to generate stable knockdown of ATM with the aim of assessing the cellular 
and molecular effects of the loss in various tumor suppressor background. HCC1937 was 
selected as it is an established BRCA1 null cell line and Capan-1 was chosen as it has no 
functional BRCA2. HeLa cells acted as a control cell line as it has both BRCA1 and 
BRCA2.  After transfection with shRNA directed against ATM, cells (HeLa, HCC1937 
and Capan-1) were selected under appropriate concentration of puromycin to eliminate 
untransfected cells. Doses for selection were decided based on time taken for control cells 
to succumb to drug. Quantitative PCR was performed to assess levels of knockdown. 
Figure 10a shows the relative expression of selected ATM knockdown clones in the 3 cell 
lines. The data obtained indicated a knockdown efficiency of 30% to 80% in HeLa cells, 
10% to 45% in HCC1937 cells and 50% ATM knockdown efficiency in Capan-1 cells. 
Best knockdown efficiency in HeLa of 80% was obtained while in HCC1937 and Capan-
1 only 50% knockdown was achieved.  Results of the qPCR were confirmed by western 
blotting.  Similar levels of ATM were detected in all control cell lines (Fig 10b, Lane 1, 7 
and 9). The different knockdown clones showed varying levels of ATM expression. H1-
H3 cells on HeLa background showed significant reduction in ATM expression (Lane 2 
to 4). C1 cells (Lane 8) showed about 50% knockdown while HCC2 and 3 (lane 11 and 
12) showed dramatic ATM knockdown. By correlating with qPCR results, HeLa shRNA 
1 (50% knockdown) and 3 (80% knockdown), HCC1937 shRNA 3 (50% knockdown) 
and Capan-1 shRNA 1 (50% knockdown) were chosen (indicate by Ì in Fig 10a) and 

























H-U H1 H2 H3 H4 H5 C-U C1 HCC-U HCC1 HCC2 HCC3 HCC4 HCC5 HCC6
β actin
ATM
H-U H1 H2 H3 H4 H5 C-U C1 HCC-U HCC1 HCC2 HCC3 HCC4 HCC5 HCC6
a
b 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Fig 10: Screening for ATM knockdowns in various cell lines by (a) quantitative PCR and 
(b) western blotting. Lanes marked with a Ì refer to clones selected for further analysis. 
H-U, C-U and HCC-U represent control HeLa, Capan-1 and HCC1937 cells. H1 to 5, C1 
and HCC1 to 6 represent ATM knockdown clones of HeLa, Capan-1 and HCC1937 
respectively.  
 
3.4. Gamma-irradiation reduces cell viability in HeLa and Capan-1 ATM knockdowns 
but not in HCC1937 background 
Short term cell survival after γ-irradiation was done to assess the contribution of ATM 
loss to cell viability in various BRCA backgrounds. Information on the effects of multiple 
losses of tumor suppressor gene functions in tumor cells would be of immense clinical 
importance. The data indicates that after irradiation, both HeLa and Capan-1 ATM 
knockdowns have lower survival compared than their respective controls (Fig 11a and 
11b). In control HeLa cells, the percentage survival decreased from 100% to 50% at 7.5 
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Gy of irradiation. In ATM knockdowns in the same background, treatment at 7.5 Gy 
decreased viability to 35% (Fig 11a). Dose dependent differences in response were not 
observed between H1 and H3. Control Capan-1 cells also exhibited dose dependent effect 
of irradiation on viability. On 7.5 Gy treatment, the percentage survival decreased from 
100% to 60% in Capan-1, while the knockdowns were significantly more sensitive at 
40% (Fig 11b). The HCC1937 ATM knockdown clone was resistant to treatment and has 
better survival than the control cells at all doses of irradiation tested (Fig 11c). The 
survival for control HCC1937 decreased from 100% to 65% at 7.5 Gy while 75% of the 










































































Fig 11: MTT assay measuring short term cell survival in (a) HeLa control and ATM 
knockdowns (b) Capan-1 control and ATM knockdown and (c) HCC1937 control and 




3.5 ATM knockdowns are more susceptible to damage by alkylating and crosslinking 
agents 
 
The cells were treated with clinically relevant genotoxins such as BCNU, MMS and 
MMC to see if ATM knockdowns are more susceptible to the cytotoxic effects of these 
drugs. In HeLa and its ATM knockdown, there is a steady and similar decrease in 
survival with increasing concentrations of BNCU (Fig 12a). Control HCC1937 cells also 
exhibited a dose dependent response to BCNU (Fig 12b). However the ATM knockdown 
in these cells showed a drastic sensitivity even to low BCNU concentrations (Fig 12b). 
While 100% cell survival was observed in HCC1937 on 64μM BCNU treatment, only 
70% cell survived in the HCC1937 ATM knockdown clone. Both Capan-1 and its ATM 
knockdown were as sensitive to BCNU treatment at very low doses. At 64μM BCNU 
treatment, about 50% of the cells survived (Fig 12c). Our results suggest that even partial 
ATM loss on a mutant BRCA1/2 background would lead to increased sensitivity to 
alkylating agent BCNU.  
 
In control HeLa cells, significant death was observed at a high dose of 320μM, MMS 
treatment. However, HeLa ATM knockdowns were not affected by the drug and the 
survival dropped only to 80% at the same MMS concentration (Fig 13a). MMS induced 
survival of 60% in HCC1937 control and its knockdown at 320 μM. Responses between 
the control and knockdown cells in this background were overlapping at all doses tested 
(Fig 13b). Both Capan-1 cells and their ATM knockdown were highly sensitive to MMS 
at 320μM treatment. Their levels of survival were similar to HeLa control at the same 
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dose. However, the shRNA clone was sensitive even at 20μM MMS, the lowest dose 
tested (Fig 13c). Comparison of the 3 control cells indicates that HCC1937 lacking 
BRCA1 were more resistant to MMS than HeLa and Capan-1 cells. However, it was clear 
that MMS sensitivity was restricted to reduced ATM expression in a compromised 
BRCA2 background. 
 
Treatment with MMC indicated that a high level of cell death in control cells was 
achieved at 80μM drug. At this concentration, 100% death was observed in HeLa and 
Capan-1 and 80% death in HCC1937 cells. HeLa and HCC1937 shRNA clones were 4- 
fold more sensitive to MMC and no survival was observed in HeLa shRNA 1/3 at 20μM 
drug (Fig 14a and 14b). Our investigations revealed no alteration to responses on ATM 
loss in Capan-1. Both Capan-1 and knockdown cells were extremely sensitive to the 
lowest tested dose (20μM). This indicated that lesions generated by MMC are poorly 
tolerated on ATM loss in all backgrounds. 






























































Fig 12: Responses of (a) HeLa control and ATM knockdowns (b) HCC1937 control and 
ATM knockdown and (c) Capan-1 control and ATM knockdown, after BCNU treatment. 





































































Fig 13: Responses of (a) HeLa control and ATM knockdowns (b) HCC1937 control and 
ATM knockdown and (c) Capan-1 control and ATM knockdown, after MMS treatment. 
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Fig 14: Responses of (a) HeLa control and ATM knockdowns (b) HCC1937 control and 
ATM knockdown and (c) Capan-1 control and ATM knockdown, after MMC treatment. 
Error bar indicates SD value on triplicate samples. 
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3.6. Gamma irradiation induced Chk2 phosphorylation is compromised in the ATM 
knockdowns 
 
In order to establish Chk2 as a target for ATM mediated phosphorylation in response to 
irradiation, AT-Tert cells were utilized. They were irradiated at a dose of 10 Gy and 
recovered for 2 hours before the cells were harvested. Data presented in Fig 15 suggest 
that Chk2 is expressed in AT-Tert cells and was not up-regulated upon irradiation. 
Phosphorylation of Chk2 was also not detected in AT-Tert before and after irradiation 
treatment (Fig 15). HeLa cells show Chk2 upregulation and phosphorylation on 
irradiation treatment. This confirmed the involvement of ATM in Chk2 mediated 












Fig 15: Western blot detection for Chk2, pChk2 and β actin expression in HeLa and AT-
Tert cells before and after γ-irradiation. While HeLa cells supported upregulation and 
phosphorylation of Chk2 on irradiation, AT-Tert cells could not support either. 
 
In order to study the effect of ATM loss on Chk2 mediated signaling and effect of 
concomitant loss of BRCA1/BRCA2 on Chk2 mediated signaling, cells were irradiated as 
earlier. They were subjected to 10 Gy of γ-irradiation and recovered for 2 h to see if Chk2 
upregulation or phosphorylation was compromised. Significant irradiation induced 
upregulation of Chk2 in HeLa, HCC1937 and Capan-1 cells were observed (Fig 16). 
Significant elevated levels of pChk2 were also observed on irradiation. ATM knockdown 
in HeLa cells caused knockdown dependent suppression of Chk2 expression (Fig 16, top 
panel, lane 8 to 10). Reduced Chk2 upregulation was detected in HeLa shRNA 1 with ~ 
45% KD (lane 9 versus 8), while detection of Chk2 on irradiation was not possible by 
western blot in HeLa shRNA 3 with ~80% ATM knockdown (Lane 10 versus 8). These 
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knockdown cells further exhibited poor phosphorylation of Chk2 on irradiation. 
Similarly, ATM knockdown in HCC1937 and Capan-1 showed 50% lower upregulation 
of Chk2 expression and phosphorylation. 
 
This indicated that loss of ATM was the direct cause of proportionally reduced Chk2 
mediated signalling events activated on irradiation. 
 
 
Fig 16: Western blot detection for Chk2, pChk2 and β actin expression in HeLa, 
HCC1937, Capan-1 and their ATM knockdown clones after γ-irradiation. Lane 1, 4, 6, 8, 
11 and 13 represent control cells and all others represent ATM knockdowns. Lane 2 and 
9 correspond to HeLa shRNA 1 and lane 3 and 10 correspond to HeLa shRNA 3. 
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3.7. Etoposide induces Chk2 expression and phosphorylation in untransfected HeLa, 
HCC1937 and Capan-1 cells 
 
Etoposide is a potent anti-tumour drug that causes DNA double strand breaks and 
transiently activates ATM. Activated ATM responds by phosphorylating a number of 
downstream targets such as H2AX, p53 and Chk2 in response to IR induced double 
strand breaks. To check the efficiency of ATM function on etoposide treatment, all 3 cell 
lines were treated with 100μM etoposide to see if Chk2 phosphorylation occurred. HeLa, 
HCC1937 and Capan-1 cells were assessed at indicated time points after recovery (Fig 
17). At similar levels of β−actin expression, both Chk2 and pChk2 were up-regulated 
after etoposide treatment in all cell lines tested. Chk2 up-regulation and phosphorylation 
occurred as early as 2h post treatment. In HeLa cells, Chk2 was upregulated and 
phosphorylated after treatment and most strongly expressed at 4 h (Fig 17, lane 7). The 
level of phosphorylation was reduced subsequently at 8h indicating that phosphorylation 
is a transient event in repair. In HCC1937 cells, lower levels of Chk2 induction was 
observed in comparison with HeLa 4h after treatment (Fig 17, lane 8). However, 
phosphorylation of Chk2 was observed. As with HeLa cells, phosphorylation levels 
dropped at 8h post treatment. In Capan-1 cells, there was a delayed but stable 
phosphorylation of Chk2 observed at 4h post treatment. Phosphorylation signaling was 
maintained at high level even at 8h post treatment. It is noted that pChk2 was detected in 
untreated HCC1937 while undetectable in HeLa and Capan-1.  
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Fig 17: Western Blot for detection of Chk2, pChk2 and β actin in HeLa, HCC1937 and 
Capan-1 cells. Lane 1, 4, 7 and 10 represent HeLa, Lane 2, 5, 8 and 11 represent 
HCC1937, Lane 3, 6, 9 and 12 represent Capan-1 cells. 
 
  
3.8. ATM knockdowns in HeLa and Capan-1 but not HCC1937 show reduced Chk2 
expression and phosphorylation after etoposide treatment 
 
After assessing the effects of etoposide on the Chk2 and pChk2 profile in control cells, 
we assessed the effect of etoposide on the validated ATM knockdown clones. Since the 
cells responded differently over time after treatment, all cells were followed for a 8h post 
treatment period. In the HeLa ATM knockdown clones, minimal Chk2 and no pChk2 
were detected before treatment (Fig 18, lane 2 and 3). Two hours after etoposide 
treatment, there was lower induction and phosphorylation of Chk2 in the knockdown 
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cells in comparison with control (Lane 4). This ability to phosphorylate Chk2 correlated 
directly to the ATM expression levels (Fig 10b). No dramatic differences were 
discernable by 8h. This suggested that Chk2 phosphorylation and upregulation was 
dramatically affected even on partial loss of ATM function. 
 
Fig 18: Chk2 and pChk2 expression after etoposide treatment in control HeLa and the 
ATM knockdowns. Panels show a blot probed for Chk2, pChk2 and β actin. Lane 1, 4, 7 
and 10 represent HeLa control, Lane 2, 5, 8 and 11 represent HeLa shRNA clone 1, Lane 
3, 6, 9 and 12 represent HeLa shRNA clone 3. 
 
Unlike HeLa, HCC1937 cells have a significant amount of Chk2 and detectable pChk2 
even when untreated (Fig 19, lane 1). This is in agreement with our earlier finding (Fig 
17, lane 2). The increase in Chk2 at 2h post-treatment is transient and expression returns 
to its basal level by 4 h. The level of pChk2 increased only modestly after treatment and 
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remained so throughout the course of experiment. ATM knockdown in a BRCA1 null 
background did not significantly alter ATM signaling though Chk2 phosphorylation was 
evidently elevated in untreated cells. Chk2 was similarly phosphorylated in KD cells as in 
control cells on etoposide treatment. 
 
Fig 19: Western blot detection for Chk2, pChk2 and β actin expression in control 
HCC1937 cells and those with reduced ATM expression after etoposide treatment. Lane 
1, 3, 5, 7 represent control HCC1937. Lane 2, 4, 6, 8 represent HCC1937 shRNA clone. 
 
In Capan-1, both Chk2 and pChk2 were up-regulated after treatment (Fig 20). Chk2 
expression in the ATM knockdown is induced after treatment but the level remained 
constant throughout the course of experiment. At all the time points, it appeared that the 
level of pChk2 in ATM knockdown is 50% lower than in control cells. 
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Similar to HeLa on etoposide treatment, upregulation of Chk2 and its phosphorylation 
(Fig 20, lane 4, 6 and 8) was marginally compromised in Capan-1 cells with partial loss 
of ATM expression in comparison to controls (Fig 20, Lane 3, 5 and 7). This 50% 
induction in Chk2 upregulation observed in ATM KD cells is in keeping with the 50% 
ATM KD achieved in this background. 
Taken together, this suggests that signaling mediated by ATM is dependent on the type of 
damage induced. Not all strand breaks generating agents lead to Chk2 upregulation and 
phosphorylation in a manner similar to IR induced upregulation and phosphorylation. 
 
Fig 20: Western blot detection for Chk2, pChk2 and β actin expression in control Capan-
1 cells and those with reduced ATM expression after etoposide treatment. Lane 1, 3, 5, 7 
represent control Capan-1. Lane 2, 4, 6, 8 represent Capan-1 shRNA clone.  
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3.9. ATM knockdowns exhibits different gene expression profiles in different 
backgrounds in comparison to control 
 
In order to elucidate the involvement of ATM in the cell cycle pathway, a PCR array was 
used to compare the different gene expressions in the various knockdown cells generated. 
The complete set of genes tested in this array can be found in the Appendix 1. Bcl2, p21, 
Cul2 and Rad9A were selected based on their significant differential expressions in 
different BRCA background.  As shown in Fig 21a, HCC1937 knockdown showed a 4-
fold higher Bcl2 expression than control cell but HeLa and Capan-1 knockdowns did not 
exhibit any such alterations. p21 is upregulated in all cells on ATM knockdown and the 
relative expression in HeLa, HCC1937 and Capan-1 knockdowns is 1.75, 1.4 and 1.9 fold 
respectively (Fig 21b). For CUL2, with the exception of HeLa, which has an upregulation 
of 1.5-fold, both HCC1937 and Capan-1 knockdown clones showed down-regulation of 
1.6 and 2.5-fold respectively (Fig 21c). Finally, HeLa, HCC1937 and Capan-1 ATM 
knockdowns showed down regulation of RAD9A at 2.5, 1.4 and 1.3 fold respectively 
(Fig 21d). This differential expression profile observed on ATM knockdown in various 
backgrounds may well explain the differential transformation and survival responses 


































































Fig 21: Expression profile of ATM knockdown on different BRCA backgrounds (a) 
BCL2, (b) p21, (c) CUL2 and (d) RAD9A. Only HeLa shRNA 3 was tested in this array. 
A complete list of all genes tested is detailed in appendix 3. 
 
3.10. Interaction of ATM with BRCA2  
 
BRCA1 is known target of ATM and these proteins interact with each other. However, no 
such report of interaction between BRCA2 and ATM exists. Our data on cellular 
responses to genotoxins suggest that BRCA2 may interact with ATM directly or 
indirectly via BRCA1. The interaction of ATM with BRCA2 was assessed by 
immunoprecipitation and the resulting immunoblot was probed for ATM in control HeLa 
cells (Fig 22). Total cell lysate was used as a positive control to show that the ATM is 
present in the lysate used for the pulldown experiment. Immunoprecipitation with ATM 
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antibody in RIPA containing 150mM or 300mM NaCl showed a positive band for ATM 
(Fig 22, Panel A, lane 2 and 4), indicating that pulldown of ATM was successful in both 
salt conditions. However, when the same samples were immunoprecipitated with BRCA2 
antibody, only 150mM NaCl condition showed a weak coprecipitation for ATM (Fig 22, 
Panel A Lane 6). Reprobing for BRCA2 pulldown indicated the BRCA2 was successfully 
immunoprecipitated only at 150mM NaCl conditions (Fig 22, Panel C, lane 6) and not at 
300mM NaCl conditions (Fig 22, Panel C, lane 3). This shows that ATM may interact 
with BRCA2 even in untreated samples at low salt conditions. The supernatant from IP 
were used to assess the amount of unbound ATM protein left after the IP (Fig 22, panel 
B). Reduced ATM was observed in supernatant samples from successful IPs (Fig 22, 
panel B, Lane 2 and 6). A normal mouse IgG was used as a negative control to rule out 
any non-specific binding to proteins of interest (Fig 22, panel A and C, lane 5). We were 
unable to detect BRCA2 in the lysate applied (lane 1, panel C) due to technical problems 
intrinsic to the protein. BRCA2 detection in lysates requires application of large amounts 
of total cellular proteins (>100μg) and even then its detection cannot be accomplished in 
such a sample after stripping with β-mercaptoethanol, Our ability to detect BRCA2 
pulldown in panel C, lane 6 was due to successful immunoprecipitation of the protein 













Fig 22: Immunoprecipitation of ATM and BRCA2 using RIPA containing 150mM or 
300mM NaCl. Panel A and C are IP samples and panel B is unbound samples after IP; 
Lane 1 is 100μg total cell lysate, Lane 2 and 4 are samples immunoprecipitated with 
ATM antibody, Lane 3 and 6 are samples immunoprecipitated with BRCA2 antibody, 
Lane 5 is sample immunoprecipitated with normal mouse IgG antibody. Panels A and B 
are probed with ATM antibody. Panel C is the same blot as in panel A probed with 
BRCA2 antibody after stripping. 
 
3.11. Knockdown of ATM promotes anchorage-independent growth in soft agar assay 
only in a BRCA2 null background 
 
After growing the cells in semi-solid media for 3 weeks, the number of colonies formed 
was manually counted. Table 1 displays the number of colonies obtained from the various 
cell lines. HeLa has 16 while HeLa shRNA 1 and 3 have 10 and 12 respectively. 
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HCC1937 and its knockdown showed 13 and 7 while Capan-1 and its knockdown have 
11 and 13 colonies respectively. 
 
Cells No of colonies ± SD
HeLa 16 ± 2 
HeLa shRNA 1 10 ± 2 
HeLa shRNA 3 12 ± 1 
HCC1937 13 ± 1 
HCC1937 shRNA 1 7 ± 2 
Capan-1 11 ± 1 
Capan-1 shRNA 1 13 ± 2 
 
Table 1: Number of colonies observed in the ATM knockdowns and their controls when 











Fig 23: Representative images (4x) of (a) control HeLa, (b) HeLa shRNA 1, (c) HeLa 
shRNA 3, (d) control HCC1937, (e) HCC1937 shRNA 1, (f) control Capan-1 and (g) 
Capan-1 shRNA 1 colonies at the end of the soft agar assay. 
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The cellular transformation assay undertaken indicated that loss of ATM compromised 
anchorage independent survival in HeLa and HCC1937 backgrounds (Table 1; Fig 23b, c 
and e). Loss of ATM on a BR2 null background caused transformation and dramatic 
survival and growth of cells (Table 1; Fig 23g).  
  
 
3.12. Gamma-irradiation reduces colony forming ability in HeLa but not Capan-1 ATM 
knockdowns 
 
The long term cell survival after γ-irradiation was also assessed for the various ATM 
knockdowns. This is relevant as irradiation is a conventional form of treatment on 
determination of ATM loss. Further, ATM knockdown on a BR2 null background 
(Capan-1) caused robust transformation (Fig 23 and Table 1). The control and ATM 
knockdown cells were irradiated at a dose of 2 or 10 Gy to see the colony forming ability 
in these cells (Fig 24). At 0 Gy, the untreated control HeLa and Capan-1 cells formed 
many colonies in comparison to their ATM knockdowns which displayed significantly 
fewer colonies. Control HCC1937 cells were poorly colony forming. Relative to the 
fewer and smaller colonies in untreated control cells, the knockdown formed larger and 
more number of colonies indicating better survival. When cells were irradiated at a dose 
of 2 Gy, there was a 40% reduction in the number of colonies in control HeLa and 
Capan-1. A reduction of 50 to 60% in the number of colonies was observed in HeLa 
shRNA 3 on irradiation. No change in colony formation in Capan-1 indicated better 
tolerance to irradiation. Although there was a reduction in number of colonies, HCC1937 
knockdown still displayed more colonies than control cells. At high dose of 10 Gy, all 
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cell lines showed poor or nil survival indicating it to be a toxic dose to all cell lines. No 
colonies were observed for HeLa and Capan-1 and their respective knockdowns. 
HCC1937 and its knockdown had a small colony at the centre of the well, which could be 
a survival artifact.  Taken together, this indicates that differential cooperativity of tumor 





Fig 24: Colony formation assay for ATM knockdowns after exposure to γ-irradiation. 
HeLa shRNA 3 cells were highly susceptible to IR but not HCC1937 or Capan-1 cells 





This study is directed at generating deeper insights into the involvement of ATM in 
cancer susceptibility. To study the pathogenic potential of a common ATM missense 
allele and the involvement of an adjacent conserved region, BAC engineering was used to 
create mutations in Atm. Such altered alleles of ATM were transfected into AT-Tert cells 
for assessment. Stable ATM knockdown in various cell lines lacking BRCA1 (HCC1937) 
or BRCA2 (Capan-1) or expressing both (HeLa) was also undertaken to assess the effects 
of multiple functional losses often observed in cancers. 
 
4.1. Generation of altered alleles of ATM 
 
The ATM missense which lies at a conserved region (exon 64) was chosen as it is 
frequently reported altered and as it lies near the PI3-kinase domain. It is possible that the 
alteration causes conformation changes to the protein and/or compromises ATM’s kinase 
activity. We also generated a deletion in a region adjacent to the missense (16 amino acid 
residues, 3’ of the missense). This C-terminal highly conserved 35 residue tail is known 
as the FATC domain (Bosotti et al., 2000). This domain has recently been reported to be 
important for regulating the kinase activity of ATM by binding regulatory proteins (Jiang 
et al., 2006).  
 
Our data indicated that deletion at the FATC region did not affect the growth of AT-Tert 
cells (Fig 8). This suggests that deletion of the FATC domain may not completely 
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obliterate ATM function, and that some basal levels of the kinase activity was retained. It 
is likely that the deleted FATC domain did not significantly alter the ATM protein 
structure. BAC missense transfections into AT-Tert cells indicated generation of 
transfected clones that failed to establish in long-term culture.  
 
Cells derived from AT patients and ATM deficient mice show hypersensitive to IR, slow 
growth in culture due to cytoskeletal defects and premature senescence (Barlow et al., 
1996). They also show end to end associations involving telomeres. Telomeres, 
consisting of (TTAGGG)n repeats and associated proteins, protect chromosomes from 
end to end fusions, incomplete replication and exonuclease degradation. Telomere 
shortening may play an important role in tumorigenesis and aging. Loss of ATM led 
telomere shortening prevents the propagation of cells by triggering cell cycle checkpoints 
when telomeres fall below a critical size. This defect is rectified by the expression of 
human telomerase reverse transcriptase (hTERT) in the AT cells. 
 
The ATM null cell line with a constitutive telomerase activity used in this study 
(designated AT-Tert) did not exhibit any of the growth arrest characteristics associated 
with AT cells. The introduction of a missense generated at exon 64 of ATM caused the 
AT-tert cells to die. This indicates that the missense is able to reverse the activity of 
TERT in these cells and allowed premature senescence, a hallmark of ATM loss. 
 
Gatti et al. (1999) proposed that missense ATM variants might differ from truncating 
ATM mutations in their effect on ATM activity and hence cancer susceptibility. They 
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postulated that certain ATM missense variants might encode functionally abnormal 
proteins that could act in a dominant-negative fashion, which would therefore have more 
substantial effects on ATM function than a single truncating mutation. Our data suggests 
that the arginine to histidine change in ATM generates a dominant negative allele that 
functions by regulating TERT activity. This is in contrast with the transformation 
observed in clinical samples carrying the missense mutation. It is therefore likely that 
multiple genetic alterations are responsible for the oncogenic transformation of cells 
expressing ATM missense. This led us to investigate the role of ATM in multiple cancer 
susceptibility backgrounds. 
 
4.2. Generation of ATM knockdowns in multiple BRCA backgrounds 
 
Our data suggested that it would be prudent to understand the contribution of ATM to 
cancer susceptibility in various BRCA background. Our approach was to knockdown 
ATM via RNA interference. Although the use of siRNA targeting ATM would be 
sufficient to cause a knockdown, the effects would be transient and the efficiency may 
vary between experiments and cell lines. Further, effects of knockdowns may not be 
apparent in mixed cultures, bearing normal and knockdown cells. To minimize these 
potential errors and obtain consistent knockdowns, generating stable clones were 
preferred. We were able to establish stable ATM knockdowns in all three backgrounds 
tested (BR1+BR2+, BR1-BR2+, BR1+BR2-).  It was observed that reduced ATM 
expression was maintained in established knockdown clones well beyond 10 passages 
after the end of selection.  
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Generation of stable ATM knockdowns required much time and the success rate varied 
among the cell lines. Knockdowns were especially laborious in the case of HCC1937 
cells due to the cell type and poor growth rate. Among the 3 cell lines, HeLa was the 
easiest cell line to generate stable ATM knockdowns and this took approximately 6 
weeks. This is followed by Capan-1 (8 weeks) and HCC1937 (10 weeks). The growth 
rate for Capan-1 and HCC1937 is slow and this hampered the generation and screening 
process. In addition, HCC1937 proved to be a difficult cell line to transfect requiring 
multiple attempts at transfection using various methods including the use of 
lipofectamine reagent, polymag/combimag, Amaxa and electroporation. 
 
To combat issues of design associated poor knockdown efficiency, we used two shRNA 
(namely A9 and A12) targeting at different regions of ATM. Our success in transfection 
with these shRNA varied among the three cell lines. For HeLa and HCC1937, A9 
appeared to cause better knockdown efficiency than shRNA A12 while we were only 
able to obtain Capan-1 transfected with A12. It is possible that higher ATM knockdown 
efficiency could not be tolerated in this background and such cells were eliminated 
during selection. 
 
4.3. Effects of ATM knockdown on cell survival 
 
A short term (72h) survival assay was undertaken to see effects of irradiation on cells 
with various multiple losses. As cells may not die within 72h period due to cell arrest and 
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repair, long term survival by clonogenic assay was also undertaken. Cells on IR, were 
thus scored for survival at 72 h and 2 weeks after IR. IR induced survival was observed 
only in HCC1937 ATM knockdown in comparison to control cells (Fig 11c). This could 
be attributed to the slow growth of these cells. However, when the cells were irradiated 
and left for colony formation for 2 weeks, better survival was obtained in knockdowns on 
a BR1- and BR2- background in comparison to controls (Fig 24, middle panel). This 
indicates that loss of ATM does not necessarily indicate susceptibility to IR. Background 
has a major role to play in responses to IR. Simultaneous loss of BRCA1/2 leads to better 
IR survival responses of tumors. 
 
4.4. Effects of drug treatment on the ATM KD 
 
It is known that IR causes DNA double stand breaks and activates ATM. However, the 
roles of ATM in the repair of damage caused by genotoxins are less studied. To elucidate 
the effects of genotoxins on ATM mediated repair, clinically relevant drugs such as 
BCNU, MMS and MMC were used. Alkylating agent BCNU is a chemotherapeutic drug 
commonly used in human intracranial tumors, lymphomas, melanomas, gastrointestinal 
cancer, etc. It damages DNA by modifying bases, cross-linking and inducing strand 
breaks. Monofunctional alkylating agent MMS, methylates DNA and these lesions are 
converted to strand breaks during cellular processing. DNA interstrand crosslinker MMC, 
links adenine and guanine bases and stalls replication. To date, radiation sensitivity marks 
ATM loss and alternate treatment modalities are rare. Our findings suggest that there is a 
significant difference in BCNU drug sensitivity on ATM knockdowns in a BR1- or BR2- 
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background. Figure 12b indicates that ATM in HCC1937 is more susceptible to the 
genotoxic effect of BCNU. This could indicate the involvement of ATM/BRCA1 alkyl 
lesion repair. Further investigation in this direction may be worthy of pursuit. Data 
presented in Fig 13 suggests that ATM loss on a BR1+BR2+ background causes 
remarkable resistance to MMS. However, all ATM knockdown cells exhibited 
heightened sensitivity to MMC (Fig 14). Responses further seem to be similar on all 
partial ATM losses (50%-80% knockdown). Taken together, this suggests that effective 
management of disease caused by ATM loss requires detailed understanding of BRCA 
background. IR may be an effective therapeutic strategy for only a subset of clinical 
manifestations. BCNU may be a prudent choice of treatment in a BR1/2 compromised 
and partial ATM function phenotypes. MMC maybe the best modality of treatment in 
absence of information on BRCA1/2 functions. 
 
4.5. Effects of ATM loss on irradiation induced regulation and phosphorylation of 
Chk2 
 
ATM phosphorylates many targets such as H2AX, p53 and Chk2. Our data from results 
in Fig 15 shows that AT-Tert cells (ATM null) do not support induction of Chk2 or 
pChk2 after 10 Gy irradiation in comparison to HeLa cells. This confirmed Chk2 as a 
target for ATM and was thus used in this study. 
 
Bakkenist and Kastan (2003) reported that IR dependent autophosphorylation of ATM 
occurred as early as 10 min in 293T cells. We observed stable signaling to Chk2 in all 3 
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control cell lines tested at 2 h post IR. Hence, assessment of knockdowns was carried out 
at this time point.  
 
Data presented in Fig 16 suggest that the presence of ATM directly correlates with the 
levels of Chk2 induction and phosphorylation to IR. This indicates that signaling events 
such as Chk2 phosphorylation triggered by IR are valid and unaltered by the presence or 
absence of BRCA gene products. 
 
4.6. Effects of etoposide treatment on the regulation of Chk2 
 
Etoposide is a topoisomerase II inhibitor that is often used in chemotherapy against 
lymphomas and other cancers (Meresse et al., 2004). We used this non-classical DNA 
double strand break creating agent to assess ATM mediated signaling. It would appear 
that induction and phosphorylation of Chk2 is highly dependent on the agent that causes 
DNA double strand break lesion. Different BRCA backgrounds have different responses 
to this damage signal.  
 
ATM knockdowns from the 3 cell lines show varying response to etoposide treatment. 
While reduced knockdown dependent Chk2 phosphorylation after treatment was 
observed in HeLa and Capan-1 cells, the same was not true for HCC1937 ATM 
knockdown cells. Loss of BRCA1 and ATM rendered detectable Chk2 and phospho-
Chk2 even in untreated control cells. This suggests that the loss of BRCA1 may 
constitutively activate Chk2 via leaky signaling through ATM. Our observation on 
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upregulation of Chk2 and pChk2 on etoposide treatment in HCC1937 shRNA cells 
further suggests dysregulation of ATM signaling responses. This could either due to 
upregulated ATM in response to etoposide treatment or availability of alternate Chk2 
regulators activated on ATM knockdown in these cells. The former is highly unlikely as 
these clones stably express the shRNA against ATM. We clarified that ATM was not 
upregulated in ATM knockdown cells in comparison with controls on etoposide 
treatment (Appendix 2). This indicates that Chk2 regulation in a BR1- background is 
unrelated to ATM function. Our analysis of ATM signaling provided only a brief 
snapshot of ATM actions on its specific target, Chk2. A detailed investigation of alternate 
signaling modalities inactivated/activated would be useful. 
 
4.7. Effects of KD on cellular transformation in a soft agar assay 
 
The assay was undertaken to understand the ability of one or more tumor suppressor 
genes loss to allow cellular transformability. The number of colonies formed in soft agar 
assay was dramatically reduced on ATM knockdowns in HeLa and HCC1937 cells. 
HCC1937 cells have intrinsically poor colonizing ability as noted in the colony forming 
assay (responses to IR) and soft agar assay. It is suggested that future experiments be 
carried out over longer times to allow for the slower growth characteristics of HCC1937 
cells. Slow growing Capan-1 cells also show poor colonies on soft agar assay. However, 
its ATM knockdowns exhibited enhanced growth potential and transformability (Fig 23). 
In the soft agar assay, although the number of colonies in Capan-1 ATM knockdown 
obtained is similar to control Capan-1, the colonies appear larger, indicating that a 
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concomitant loss of ATM and BRCA2 may confer a more aggressive phenotype in 
tumors. These cells further seem resistant to IR treatments as indicated by the colony 
forming assay (Fig  24). 
 
4.8. Cellular involvements of ATM 
 
AT cells divide poorly in culture and require telomerase to stabilize their growth and 
maintenance. We did not note alterations to growth characteristics in HeLa, HCC1937 or 
Capan-1 cells on ATM knockdown. 
 
Though not directly indicated, we assessed the effects of knockdown on the cells ability 
to cycle with the aim to clarify the responses of knockdown clones to genotoxins. PCR 
array with 84 genes involved in cell cycle pathway was thus used in the study. 
 
Bcl2 is a pro-survival protein which is dramatically upregulated in HCC1937 ATM 
knockdown (Fig 21). This indicated that ATM is a direct / indirect regulator of Bcl2 
expression via BRCA1. A previous report by Freneaux et al. (2000) suggests that 
BRCA1 directly regulates Bcl2 expression. Loss of BR1 led to reduced expression of 
Bcl2 in tumors. Our results further suggest that concomitants loss of ATM and BR1 may 
lead to Bcl2 upregulation by mechanisms as yet unclear. This upregulation of Bcl2 likely 
explains the increased survival of ATM knockdown on this cellular background in 
response to irradiation (short term and long term survival).  
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p21 is a Cdk2 inhibitor which causes G1 arrest in a p53 dependent manner (Xu et al., 
1998). Our data indicates that ATM knockdown in all 3 cell lines causes higher p21 
expression. Xu et al. (1998) suggested that ATM null mouse embryo fibroblasts showed 
increased p21 stability and this caused arrested growth in these cells. However, increased 
p21 in our shRNA model did not correlate with altered doubling time or arrest in growth. 
Since the cell lines used in this study do not express p53, the p21 upregulation was 
indicated to be a p53 independent event. This failure to arrest may probably be due to 
altered downstream signaling. It would also be interesting to see if the increased mRNA 
levels for p21 result in increased protein expression. Overexpression of p21 is often 
observed in breast cancer, gastric cancer, gliomas, etc and is used as a poor prognostic 
marker in cancers (Xu et al., 1998). Hence, it will be interesting to see if reactivation of 
p53 pathway in these cells would lead to arrested growth.  
 
Loss of BRCA1 or BRCA2 with the simultaneous downregulation of ATM resulted in 
lower Cul2 expression. CUL-2 is a member of the cullin family. These proteins function 
as central components in multisubunit cullin-RING ubiquitin ligase complexes (E3) 
(Petroski and Deshaies, 2005). Since cullins are generally involved in ubiquitination and 
cycling of cyclin, it appears that ATM directly regulates Cul2 expression. In the presence 
of both BRCA gene products, loss of ATM induced upregulation of cullins. This may 
prove important for rapid cycling through cell division and tolerance to genotoxins. 
Interestingly, the expression phenotype of Capan-1 ATM knockdown cells of unaltered 
Bcl2, higher p21 and reduced Cul2 should indicate poor survival of these cells in 
comparison to controls. The colony forming assay however indicated heightened 
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transformation of these cells. A more comprehensive screen for the expression profile of 
these cells is thus warranted. 
 
Chen et al. (2001) suggested that ATM is responsible for Rad9 hyper-phosphorylation in 
response to IR. This phosphorylation of Rad9 is important for checkpoint activation. Our 
data suggests that loss of ATM in a HeLa background causes significant decrease in Rad9 
expression but not in other cell lines tested. This reduced expression induced escape from 
cell cycle arrest may explain the colonizing ability of these cells on IR treatment. 
 
4.9. Possible interaction of ATM with BRCA2 
 
To date there are no suggestions of ATM interaction with BRCA2. Studies on ATM 
interaction with BRCA1 (Wang et al., 2000) and interaction between BRCA1 and 
BRCA2 are documented (Yoshida and Miki, 2004). Based on our data discussed earlier, 
it is likely that ATM together with BRCA2 is important for cellular transformation. Thus, 
we assessed possible interaction by immunoprecipitation. Indeed, our data indicates such 
an interaction does exist under certain conditions. Cellular BRCA2 and ATM interact 
with each other weakly in the absence of DNA. No interaction was observed in chromatin 
bound proteins (high salt elution). Samples immunoprecipitated with ATM antibody 
when reprobed for BRCA2 (Fig 22; Panel C, lane 2 and 4), did not show any co-ip of 
BRCA2. This could be due to the antibody used to immunoprecipitate ATM which may 
sterically hinder the interaction with BRCA2. Our results also indicate that this 
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interaction may be transient and weak. It may be more prominent under special 





AT carriers are susceptible to breast cancer notably in young women. Missense mutations 
on the ATM gene are often found in these patients. Unclassified missense mutations 
outside the PI3-kinase domain are predicted to function like normal ATM. However, the 
missense mutation in exon 64 generated in this study appears to have a dysregulatory 
effect on telomerase function, causing AT-Tert cells to die in culture. This alteration thus 
has transformation potential possibly in other compromised backgrounds. Yet, this 
potential does not exist on deletion of the FATC domain, a conserved region adjacent to 
the missense. The deletion likely does not destabilize the protein structure, allows for 
basal kinase function to continue, and does not regulate telomerase function. 
 
The level of ATM knockdowns correlates with IR induced ATM mediated Chk2 
phosphorylation in all cell lines tested. However, we did not detail all ATM mediated 
signaling responses due to paucity of funds to run a genome wide screen. Drug treatments 
on ATM knockdown in various BRCA backgrounds exhibited differential sensitivity and 
survival responses. It seemed that even a partial compromise of multiple functions in a 
single cell led to dramatically altered responses. This was also true for irradiation induced 
survival (short and long term). 
 
The colony forming assay and soft agar assay shows that HCC1937 ATM knockdown 
forms fewer colonies. These cells however, would prove more aggressive if established 
as they show an increase in Bcl2 and decrease in Rad9A. Partial functional loss ATM 
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along with the loss of BRCA2 function (in Capan-1 ATM knockdowns) leads to 
aggressive growth in soft agar assays and heightened resistance to irradiation treatment. 
This is of significance as cells lacking BRCA2 or ATM alone exhibit radiosensitivity. 
Both proteins are believed to be involved in the DNA double strand break repair 
pathway. However simultaneous loss (even partial) causes radioresistance. 
 
Induction and phosphorylation pattern varies with BRCA background and the type of 
treatment. Cells with ATM loss on multiple backgrounds are most sensitive to MMC 
treatment and BCNU may be effective in compromised BRCA backgrounds. This 
indicates that the cellular transformation event and responses to IR are unrelated to 
compromised ATM mediated signaling. 
 
We conclude that the interplay of ATM with different BRCA gene products may lead to 
different sensitivity to treatments and suggest that in the absense of information on 
BRCA status, tumors should be better managed by treatment with DNA crosslinker 




6. FUTURE DIRECTIONS 
 
The use of BAC recombineering provides a useful platform to create mutations and study 
effects of genomic alterations at endogenous expression levels in a cell. In order to 
further elucidate the functions of the altered missense allele, an over-expression model 
system may be utilized. By using this system, it is likely possible to drive cellular 
transformation in multiple tumor suppressor gene backgrounds. Applying this system to 
AT-Tert cells may help to understand how ATM mutations can affect cellular functions. 
 
Cancer is a progressive disease that exhibits multiple genetic alterations. A genome wide 
screen would thus be useful in characterizing the ATM knockdowns and developing a 
signature for effects in different tumor suppressor gene background. This signature could 
be used to predict response to genotoxins, direct drug choices and develop universally 
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ABL1 1.08 1.00 1.15 CUL2 1.65 -1.55 1.05 
ANAPC2 1.13 -1.47 -1.17 CUL3 -1.20 -1.23 1.41 
ANAPC4 1.27 -1.13 -1.04 DDX11 1.46 -1.48 1.05 
DIRAS3 1.27 -1.04 1.27 DNM2 -1.07 -1.26 -1.07 
ATM -1.35 -1.26 -1.31 E2F4 -1.24 -1.17 -1.41 
ATR -1.09 -1.05 -1.15 GADD45A 1.08 1.52 -1.09 
BAX -1.15 1.03 -1.14 GTF2H1 -1.08 1.20 -1.06 
BCCIP -1.23 1.20 -1.17 GTSE1 -1.11 -1.29 1.49 
BCL2 1.36 4.03 1.23 HERC5 -1.66 1.22 1.03 
BIRC5 -1.36 1.07 -1.19 HUS1 -1.11 1.19 -1.71 
BRCA1 1.06 -1.13 -1.17 KNTC1 1.13 1.06 -1.42 
BRCA2 1.10 -1.23 -1.13 KPNA2 -1.24 -1.07 -1.45 
CCNB1 -1.04 -1.26 1.04 MAD2L1 -1.09 -1.39 -1.22 
CCNB2 -1.19 -1.22 -1.32 MAD2L2 -1.18 -1.01 -1.38 
CCNC -1.02 -1.13 -1.27 MCM2 1.01 -1.12 1.02 
CCND1 -1.11 -1.53 -1.26 MCM3 -1.03 -1.18 -1.36 
CCND2 -1.04 1.57 1.04 MCM4 1.02 -1.97 -1.27 
CCNE1 -1.01 1.24 1.02 MCM5 1.07 -1.64 -1.02 
CCNF 1.01 -1.08 -1.14 MKI67 -1.25 1.05 1.06 
CCNG1 1.13 1.72 -1.06 MNAT1 1.01 1.01 -1.31 
CCNG2 -1.02 -1.12 1.28 MRE11A -1.03 -1.55 -1.33 
CCNH -1.10 -1.52 -1.54 NBN -1.22 -1.19 -1.15 
CCNT1 1.09 1.28 -1.17 PCNA 1.05 -1.19 1.03 
CCNT2 1.36 -1.22 -1.36 RAD1 -1.46 -1.46 -1.17 
CDC16 1.05 -1.32 1.34 RAD17 -1.24 -1.16 -1.13 
CDC2 -1.01 1.01 -1.29 RAD51 -1.31 -1.43 -1.18 
CDC20 -1.39 -1.24 1.05 RAD9A -2.49 -1.36 1.29 
CDC34 -1.11 -1.19 1.06 RB1 1.09 -1.10 -1.14 
CDK2 1.01 -1.29 -1.14 RBBP8 1.22 -1.28 -1.01 
CDK4 -1.14 -1.25 -1.35 RBL1 1.08 -1.10 -1.62 
CDK5R1 -1.20 1.44 -1.18 RBL2 -1.25 -1.38 -1.06 
CDK5RAP1 -1.04 1.18 -1.13 RPA3 1.29 -1.18 -1.11 
CDK6 -1.55 -1.03 1.65 SERTAD1 -1.14 -1.18 1.32 
CDK7 -1.26 -1.14 1.13 SKP2 -1.40 -1.29 -1.21 
CDK8 -1.02 1.03 1.01 SUMO1 -1.06 -1.30 1.17 
CDKN1A 1.75 1.35 1.93 TFDP1 -1.19 1.10 -1.02 
CDKN1B -1.24 -1.45 -1.14 TFDP2 1.06 -1.08 -1.14 
CDKN2A -1.79 1.63 1.04 TP53 -1.02 -1.36 -1.07 
CDKN2B -1.92 -1.87 1.04 UBE1 -1.04 1.20 1.01 
CDKN3 1.02 -1.18 -1.14 B2M 1.34 1.11 -1.29 
CHEK1 -1.05 -1.55 1.05 HPRT1 -1.07 -1.65 1.04 
CHEK2 -1.11 -1.25 -1.20 RPL13A 1.16 1.14 1.05 
CKS1B -1.17 -1.07 -1.14 GAPDH -1.03 1.28 1.17 
CKS2 -1.18 -1.40 -1.51 ACTB -1.41 1.02 -1.01 
CUL1 -1.16 -1.27 -2.40 Shaded regions are genes selected for analysis 
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Western blot detection for ATM and β actin expression in HeLa, HCC1937, Capan-1 and 
their respective ATM knowndown clones before and after 2 hours of etoposide treatment. 
H-U, C-U and HCC-U represent control HeLa, Capan-1 and HCC1937 cells. H1 and H3, 
HCC3 and C1 represent ATM knockdown clones of HeLa, HCC1937 and Capan-1 









BRCA1 expression in HeLa and HCC1937 cells was probed with an antibody against the 
C- terminal of BRCA1. Alexa 488-labeled Goat anti-mouse IgG (H+L) (Molecular 
Probes, USA) secondary antibody was used to visualize expression. DAPI was used to 
stain the nucleus of the cells. HeLa cells express full length BRCA1 in their nucleus 








BRCA2 expression in HeLa and Capan-1 cells was assessed with a wild type anti-
BRCA2 antibody. Alexa 568-labeled Goat anti-rabbit IgG (H+L) (Molecular Probes, 
USA) secondary antibody was used to visualize expression. DAPI was used to stain the 
nucleus of the cells. BRCA2 is localized in the nucleus of HeLa cells (positive control). 
Capan-1 expresses a truncated dysfunctional form of BRCA2 in the cytoplasm.  
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Appendix 4 
Chemical composition of media 
Luria-Bertani broth (LB), pH 7.0 
Bacto-tryptone  10 g 
Bacto-yeast extract  5 g 
NaCl    5g 
Double distilled water  1000 ml 
 
SOC medium, pH 7.0 
Bacto-tryptone  20 g 
Bacto-yeast extract  5 g 
NaCl    0.5 g 
KCl    0.186 g 
Double distilled water  1000 ml 
Add 20ml of sterile 1M glucose before use. 




Multiple representative images (20x) of AT-Tert BACAtm (missense) cells during (a-d) 
or after release from selection (e-h). 
